Intellectual Property Waiver of COVID-19 Vaccines and Treatments – An effective remedy?
Recent months have seen intensified global calls for an intellectual property waiver of COVID-19 related vaccines, treatments and related products. The proposal for a TRIPS waiver, made initially by India and South Africa last October, received additional impetus in May when U.S announced its initial support of the waiver and the text-based negotiations at WTO TRIPS Council. In light of these developments, this webinar will address the ongoing debates whether a waiver is the most effective and sustainable remedy in order to facilitate affordable access and promote production capacity, or if there is reason to consider other options.
This webinar is moderated by Professor Timo Minssen (Director, CeBIL). It brings together different perspectives on the matter, featuring Professor Duncan Matthews (Queen Mary Intellectual Property Research Institute, Queen Mary University, UK) and Mr. Prashant Reddy (Patent Lawyer, India).
Registration
Please register here no later than 24 September 2021, 10:00.
Link will be sent post registration.
Materials
- US U-Turn on COVID IP Waiver Alone Will Not Solve Vaccine Crisis – Intellectual Property Is an Important Part of the Debate, but Greater Transparency Is Required
-
‘No-one is Safe Until Everyone is Safe’ – Patent Waiver, Compulsory Licensing and COVID-19
-
AIPPI Position Paper: TRIPS Agreement and the COVID-19 Waiver
-
Addressing Exclusivity Issues During the COVID-19 Pandemic and Beyond
-
Academic Open Letter in Support of the TRIPS Intellectual Property Waiver Proposal